RPRX Royalty Pharma plc - Class A

  1. Stocks
  2. Healthcare
  3. NASDAQ: RPRX

Price (delayed)

$58.61

Market cap

$33.7B

P/E Ratio

31.18

Dividend/share

$0.93

EPS

$1.88

Enterprise value

$41.85B

?
Relative Growth: Rel. Growth: 59
Relative Strength: Rel. Strength: 83
Relative Valuation: Rel. Valuation: 19
Relative Profitability: Rel. Profitability: 77
Highlights
The company's quick ratio has surged by 121% YoY and by 6% QoQ
The revenue has increased by 10% YoY and by 3.9% from the previous quarter
The P/E is 31% lower than the 5-year quarterly average of 45.5 but 29% higher than the last 4 quarters average of 24.1
The net income has contracted by 20% YoY
Royalty Pharma's EPS has decreased by 19% YoY and by 2.1% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: ANIP ABT LLY

Key stats

What are the main financial stats of RPRX

RPRX stock price

How has the Royalty Pharma stock price performed over time
Intraday
-0.24%
1 week
-8.36%
1 month
1.42%
1 year
59.7%
YTD
51.68%
QTD
4.53%

Financial performance

How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.54B
Gross profit
$2.54B
Operating income
$1.51B
Net income
$815M
Gross margin
100%
Net margin
32.1%
Royalty Pharma's net margin has decreased by 28% YoY and by 6% QoQ
The operating margin has declined by 25% year-on-year and by 8% since the previous quarter
The net income has contracted by 20% YoY
The operating income has contracted by 18% YoY and by 4.8% from the previous quarter

Price vs fundamentals

How does RPRX's price correlate with its fundamentals

Growth

What is Royalty Pharma's growth rate over time

Valuation

What is Royalty Pharma stock price valuation
RPRX P/E details
P/E
31.18
P/B
3.45
P/S
10.29
EV/EBIT
35.59
EV/EBITDA
35.59
EV/Sales
16.5
The P/E is 31% lower than the 5-year quarterly average of 45.5 but 29% higher than the last 4 quarters average of 24.1
Royalty Pharma's EPS has decreased by 19% YoY and by 2.1% QoQ
RPRX's P/B is 64% above its 5-year quarterly average of 2.1 and 33% above its last 4 quarters average of 2.6
RPRX's equity is up by 3% year-on-year
The P/S is 54% above the 5-year quarterly average of 6.7 and 29% above the last 4 quarters average of 8.0
The revenue has increased by 10% YoY and by 3.9% from the previous quarter

Efficiency

How efficient is Royalty Pharma business performance
The ROA has decreased by 28% YoY and by 4.7% from the previous quarter
RPRX's ROE is down by 19% YoY and by 3.5% from the previous quarter
The ROIC is down by 18% YoY
Royalty Pharma's return on sales has decreased by 17% YoY and by 2.9% QoQ

Dividends

What is RPRX's dividend history
Dividend details
DPS
$0.93
Dividend yield
1.58%
Payout ratio
49.2%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 98% more than its total liabilities
The current ratio has surged by 122% year-on-year and by 5% since the previous quarter
The company's quick ratio has surged by 121% YoY and by 6% QoQ
Royalty Pharma's debt is 8% lower than its equity
Royalty Pharma's debt has increased by 12% YoY
The debt to equity has increased by 10% YoY and by 2.2% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.